International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 009-013
HYPOFRACTIONATED RADIOTHERAPY WITH HIGH DOSE FRACTIONS IN GLIOBLASTOMA MULTIFORME PATIENTS WITH POOR PERFORMANCE STATUS
MUSTAFA İZMİRLİ1, FUAT YAMAN1, YAKUP BÜYÜKPOLAT1, ÖMÜR ALAN1, SÜLEYMAN ALTIN1, MUSTAFA ÜNSAL1
SSK Okmeydanı Eğitim ve Araştırma Hastanesi Radyasyon Onkolojisi Kliniği, İSTANBUL
Keywords: glioblastoma multiforme, radiotherapy, hypofraction, prognostic factors
Since long lasting tumor control and survival can not be achieved with coventional radiotherapy in patients with glioblastoma multiforme, different fractionation schedules and radiation sensitizer were tried with no avail. Studies have shown that therapies performed had not improved survival and had only achieved palliative effects. In our clinics between 1994 and 1998, hypofractionated radiotherapy with high dose fractions (20-30 Gy/10 Gy fx/with 10 day intervals) was applied to 58 glioblastoma multiforme patients with poor performance status. Anti-edematous treatment was initiated concomitantly. Median survival time was 19 weeks. In post treatment clinico-neurological assesment complete or partial response (58.6%; 34/58) was achieved. As a result, the side effects of hypofractionated radiotherapy with high dose fractions in glioblastoma multiforme patients with poor performance status were found to be tolerable, and its effects on quality of life and survival were comparable with other fractionation schedules.
MUSTAFA İZMİRLİ1, FUAT YAMAN1, YAKUP BÜYÜKPOLAT1, ÖMÜR ALAN1, SÜLEYMAN ALTIN1, MUSTAFA ÜNSAL1
SSK Okmeydanı Eğitim ve Araştırma Hastanesi Radyasyon Onkolojisi Kliniği, İSTANBUL
Keywords: glioblastoma multiforme, radiotherapy, hypofraction, prognostic factors
Since long lasting tumor control and survival can not be achieved with coventional radiotherapy in patients with glioblastoma multiforme, different fractionation schedules and radiation sensitizer were tried with no avail. Studies have shown that therapies performed had not improved survival and had only achieved palliative effects. In our clinics between 1994 and 1998, hypofractionated radiotherapy with high dose fractions (20-30 Gy/10 Gy fx/with 10 day intervals) was applied to 58 glioblastoma multiforme patients with poor performance status. Anti-edematous treatment was initiated concomitantly. Median survival time was 19 weeks. In post treatment clinico-neurological assesment complete or partial response (58.6%; 34/58) was achieved. As a result, the side effects of hypofractionated radiotherapy with high dose fractions in glioblastoma multiforme patients with poor performance status were found to be tolerable, and its effects on quality of life and survival were comparable with other fractionation schedules.